IMAB News and Press, I-MAB From 11/02/23

2023-11-02 10:07:57 ET More on I-Mab, Morphic, etc. Morphic Holding: The Price Drop Is Very Interesting I-Mab: Why This Company Trades At A Third The Value Of Its Cash I-Mab (IMAB) Q2 2023 Earnings Call Transcript MorphoSys expects a 5% surge in Monjuvi sales...

Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN) PR Newswire FDA granted Breakthrough Therapy Designation for felzartamab in PMN upon positive clinical data from M-PLACE, a Phase 2 study ...

I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023 PR Newswire ROCKVILLE, MD , U.S. and SHANGHAI, China , Nov. 1, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringi...

I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023 PR Newswire ROCKVILLE, Md. and SHANGHAI, China , Oct. 16, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to ...

2023-10-15 07:15:00 ET Summary Suzhou MediLink Therapeutics out-licenses global rights for its HER3 antibody-drug conjugate candidate to BioNTech in a $1.1 billion deal. Beijing AI drug discovery company BioMap forms a strategic collaboration with Sanofi to co-develop new protein ...

I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503 PR Newswire - Among 14 efficacy-evaluable patients in the ongoing Phase 1 study, one achieved a complete response, one had partial response and two unconfirmed partial responses; ma...

2023-10-01 03:30:00 ET Summary Adlai Nortye completes a $97.5 million IPO on NASDAQ, with its lead drug in a Phase III clinical trial for head and neck squamous cell carcinoma. Nanjing Triastek raises $20 million in a Pre-C financing round to support the development of its 3D prin...

2023-09-13 16:59:36 ET Summary Chinese biotech company I-Mab faces challenges in attracting US capital due to lack of transparency and difficulty in valuing its pipeline. I-Mab has a late-stage pipeline with 20 assets and over $400 million in cash, but its market cap is only aroun...

2023-09-03 03:45:00 ET Summary Shanghai GenFleet Technologies partners with Verastem in a deal worth up to $625.5 million for three preclinical small-molecule candidates for RAS pathway-driven cancers. Shanghai Kangpu Biopharmaceuticals raises $13.8 million in a B funding round to...

2023-08-17 12:26:06 ET I-Mab (IMAB) Q2 2023 Earnings Call Transcript August 17 2023, 08:00 AM ET Company Participants Tyler Ehler - Senior Director for IR Raj Kannan - CEO John Hayslip - CMO Richard Yeh - Interim CFO and COO Andrew Zhu - President and Hea...